Top

Published in:

Open Access 01-05-2019 | Original Article

Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China

Authors: Kai Liu, Fan Feng, Xin-zu Chen, Xin-yi Zhou, Jing-yu Zhang, Xiao-long Chen, Wei-han Zhang, Kun Yang, Bo Zhang, Hong-wei Zhang, Zong-guang Zhou, Jian-kun Hu

Published in: Gastric Cancer | Issue 3/2019

Abstract

Background

The new 8th TNM system attributes AEG Siewert type II to esophageal classification system. However, the gastric and esophageal classification system which was more suitable for type II remains in disputation. This study aimed to illuminate the 8th TNM-EC or TNM-GC system which was more rational for type II, especially for patients underwent transhiatal approaches.

Methods

We collected the database of patients with AEG who underwent radical surgical resection from two high-volume institutions in China: West China Hospital (N = 773) and Xi Jing Hospital of Fourth Military University (N = 637). The cases were randomly matched into 705 training cohort and 705 validation cohort. All the cases were reclassified by the 8th edition of TNM-EC and TNM-GC. The distribution of patients in each stage, the hazard ratio of each stage, and the separation of the survival were compared. Multivariate analysis was performed using the Cox proportional hazard model. Comparisons between the different staging systems for the prognostic prediction were performed with the rcorrp.cens package in Hmisc in R (version 3.4.4. http://www.R-project.org/). The validity of these two systems was evaluated by Akaike information criterion (AIC) and concordance index (C-index).

Results

By univariate analysis, the HRs from stage IA/IB to stage IV/IVB were monotonously increased according to TNM-GC scheme in both cohorts (training 2.63, 3.91, 5.02, 8.64, 15.51 and 29.64; validation 1.54, 3.55, 4.91, 7.14, 11.67, 18.71 and 48.32) whereas only a fluctuating increased tendency was found when staged by TNM-EC. After the multivariate analysis, TNM-GC (P < 0.001), TNM-EC (P = 0.001) in training cohort and TNM-GC (P < 0.001) TNM-EC (P < 0.001) in the validation cohort were both independent prognostic factors. The C-index value for the TNM-GC scheme was larger than that of TNM-EC system in both training (0.721 vs. 0.690, P < 0.001) and validation (0.721 vs. 0.696, P < 0.001) cohorts. After stratification analysis for Siewert type II, the C-index for TNM-GC scheme was still larger than that of TNM-EC in both training (0.724 vs. 0.694, P = 0.005) and validation (0.723 vs. 0.699, P < 0.001) cohorts.

Conclusions

The 8th TNM-GC scheme is superior to TNM-EC in predicting the prognosis of AEG especially for type II among patients underwent transhiatal approaches.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. https://doi.org/10.1002/ijc.25516.CrossRefPubMed

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. https://doi.org/10.1016/j.ejca.2009.12.014.CrossRefPubMed

Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25(1):16–27. https://doi.org/10.1158/1055-9965.CrossRef

Yasuda K, Shiraishi N, Suematsu T, Yamaguchi K, Adachi Y, Kitano S. Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer. 1999;85(10):2119–23.CrossRefPubMed

Okada K, Fujisaki J, Yoshida T, Ishikawa H, Suganuma T, Kasuga A, et al. Long-term outcomes of endoscopic submucosal dissection for undifferentiated-type early gastric cancer. Endoscopy. 2012;44(2):122–7. https://doi.org/10.1055/s-0031-1291486.CrossRefPubMed

Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017;8(24):57654–69. https://doi.org/10.18632/oncotarget.CrossRefPubMedPubMedCentral

Liu K, Yang K, Zhang WH, Chen XZ, Chen XL, Zhang B, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988–2012: a single-institution, high-volume experience in China. Ann Surg. 2016;263(1):88–95. https://doi.org/10.1097/SLA.0000000000001148.CrossRefPubMed

Liu K, Zhang WH, Chen XZ, Chen XL, Yang K, Zhang B, et al. Comparison on clinicopathological features and prognosis between esophagogastric junctional adenocarcinoma (Siewert II/III Types) and distal gastric adenocarcinoma: retrospective cohort study, a single institution, high volume experience in China. Medicine (Baltimore). 2015;94(34):e1386. https://doi.org/10.1097/MD.0000000000001386.CrossRef

Sobin LH. TNM: principles, history, and relation to other prognostic factors. Cancer. 2001;91(8 suppl):1589–92.CrossRefPubMed

10.

Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10783 patients with gastric cancer. Gastric Cancer. 1998;1(2):125–33.CrossRefPubMed

11.

Warneke VS, Behrens HM, Hartmann JT, Held H, Becker T, Schwarz NT, et al. Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol. 2011;29(17):2364–71. https://doi.org/10.1200/JCO.2010.34.4358.CrossRefPubMed

12.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):9–99. https://doi.org/10.3322/caac.21388.CrossRef

13.

Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329–38. https://doi.org/10.1007/s10120-015-0575-z.CrossRefPubMed

14.

Sobin LH, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. New York: Wiley; 2009. pp. 66–72.

15.

Hasegawa S, Yoshikawa T, Aoyama T, Hayashi T, Yamada T, Tsuchida K, et al. Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol. 2013;20(3):773–9. https://doi.org/10.1245/s10434-012-2780-x.CrossRefPubMed

16.

Suh YS, Han DS, Kong SH, Lee HJ, Kim YT, Kim WH, et al. Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012;255(5):908–15. https://doi.org/10.1097/SLA.0b013e31824beb95.CrossRefPubMed

17.

Gertler R, Stein HJ, Loos M, Langer R, Friess H, Feith M. How to classify adenocarcinomas of the esophagogastric junction: as esophageal or gastric cancer? Am J Surg Pathol. 2011;35(10):1512–22. https://doi.org/10.1097/PAS.0b013e3182294764.CrossRefPubMed

18.

von Rahden BH, Feith M, Stein HJ. Carcinoma of the cardia: classification as esophageal or gastric cancer? Int J Colorectal Dis. 2005;20(2):89–93.CrossRef

19.

In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017;24(12):3683–91. https://doi.org/10.1245/s10434-017-6078-x.CrossRefPubMed

20.

Rice TW, Apperson-Hansen C, DiPaola LM, Semple ME, Lerut TE, Orringer MB, et al. Worldwide Esophageal Cancer Collaboration: clinical staging data. Dis Esophagus. 2016;29(7):707–14. https://doi.org/10.1111/dote.12493.CrossRefPubMed

21.

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19. https://doi.org/10.1007/s10120-016-0622-4.CrossRef

22.

Johnson ML, Gordon HS, Petersen NJ, Wray NP, Shroyer AL, Grover FL, et al. Effect of definition of mortality on hospital profiles. Med Care. 2002;40(1):7–16.CrossRefPubMed

23.

Siewert JR, Stein HJ. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg. 1998;85(11):1457–9.CrossRefPubMed

24.

Takeshi Sano DG, Coit HH, Kim H, Roviello F, Kassab P, Wittekind C, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer. 2017;20(2):217–25. https://doi.org/10.1007/s10120-016-0601-9.CrossRefPubMed

25.

Deng J, Zhang R, Wu L, Zhang L, Wang X, Liu Y, et al. Superiority of the ratio between negative and positive lymph nodes for predicting the prognosis for patients with gastric cancer. Ann Surg Oncol. 2015;22(4):1258–66. https://doi.org/10.1245/s10434-014-4121-8.CrossRefPubMed

26.

Huitzil-Melendez FD, Capanu M, O’Reilly EM, Duffy A, Gansukh B, Saltz LL, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010;28(17):2889–95. https://doi.org/10.1200/JCO.2009.25.9895.CrossRefPubMedPubMedCentral

27.

Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, et al. Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg. 2006;30(10):1864–9.CrossRefPubMed

28.

Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325(16):1132–6.CrossRefPubMed

29.

Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals. Cancer. 2010;116(16):3763–73. https://doi.org/10.1002/cncr.25146.CrossRefPubMed

30.

Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH. Lymphadenectomy extent is closely related to long-term survival in esophageal cancer. Eur J Cardiothorac Surg. 2007;31(2):154–60.CrossRefPubMed

31.

Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. Ann Surg. 2011;254(6):894–906. https://doi.org/10.1097/SLA.0b013e3182263781.CrossRefPubMed

32.

Zhou Z, Zhang H, Xu Z, Li W, Dang C, Song Y. Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction. World J Surg Oncol. 2015;10:197. https://doi.org/10.1186/s12957-015-0613-7.CrossRef

33.

Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005;90(3):139–46.CrossRefPubMed

34.

Parry K, Haverkamp L, Bruijnen RC, Siersema PD, Ruurda JP, van Hillegersberg R. Surgical treatment of adenocarcinomas of the gastro-esophageal junction. Ann Surg Oncol. 2015;22(2):597–603. https://doi.org/10.1245/s10434-014-4047-1.CrossRefPubMed

35.

Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer. 2017;20(Suppl 1):69–83. https://doi.org/10.1007/s10120-016-0663-8.CrossRefPubMed

36.

Huang Q, Shi J, Feng A, Fan X, Zhang L, Mashimo H, et al. Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System. Mod Pathol. 2011;24(1):138–46. https://doi.org/10.1038/modpathol.2010.183.CrossRefPubMed

37.

Piso P, Werner U, Lang H, Mirena P, Klempnauer J. Proximal versus distal gastric carcinoma—what are the differences? Ann Surg Oncol. 2000;7(7):520–5.CrossRefPubMed

38.

Cancer Genome Atlas Research Network, Analysis Working Group, Asan University, BC Cancer Agency, Brigham and Women’s Hospital, Broad Institute, Brown University, Case Western Reserve University, Dana-Farber Cancer Institute, et al. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169–75. https://doi.org/10.1038/nature20805.CrossRef

39.

Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, et al. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206(2):306–10. https://doi.org/10.1016/j.jamcollsurg.2007.06.306.CrossRefPubMed

40.

Kim HI, Cheong JH, Song KJ, An JY, Hyung WJ, Noh SH, et al. Staging of adenocarcinoma of the esophagogastric junction: comparison of AJCC 6th and 7th gastric and 7th esophageal staging systems. Ann Surg Oncol. 2013;20(8):2713–20. https://doi.org/10.1245/s10434-013-2898-5.CrossRefPubMed

Title: Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China
Authors: Kai Liu
Fan Feng
Xin-zu Chen
Xin-yi Zhou
Jing-yu Zhang
Xiao-long Chen
Wei-han Zhang
Kun Yang
Bo Zhang
Hong-wei Zhang
Zong-guang Zhou
Jian-kun Hu
Publication date: 01-05-2019
Publisher: Springer Singapore
Published in: Gastric Cancer / Issue 3/2019
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI: https://doi.org/10.1007/s10120-018-0890-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)

Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma

The role of oxaliplatin in the adjuvant setting of different Lauren’s type of gastric adenocarcinoma after D2 gastrectomy: a real-world study

The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells

CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial

Long-term quality of life and nutrition status of the aboral pouch reconstruction after total gastrectomy for gastric cancer: a prospective multicenter observational study (CCOG1505)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page